These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 29535974

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H, Yao X, Qiu Z, Sun J, Qiao Y, Zhang M, Wang M, Cui S, He Y.
    J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
    [Abstract] [Full Text] [Related]

  • 5. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L.
    J Virol; 2017 Jan 01; 91(1):. PubMed ID: 27795416
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y, Ding X, Yu D, Chong H, He Y.
    J Virol; 2019 Dec 12; 94(1):. PubMed ID: 31619552
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X, Zhang X, Chong H, Zhu Y, Wei H, Wu X, He J, Wang X, He Y.
    J Virol; 2017 Sep 15; 91(18):. PubMed ID: 28659478
    [Abstract] [Full Text] [Related]

  • 13. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L, Tong P, Yu X, Pan C, Zou P, Chen YH, Jiang S.
    Biochim Biophys Acta; 2012 Dec 15; 1818(12):2950-7. PubMed ID: 22867851
    [Abstract] [Full Text] [Related]

  • 14. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S, Zhao Q, Debnath AK.
    Curr Pharm Des; 2002 Dec 15; 8(8):563-80. PubMed ID: 11945159
    [Abstract] [Full Text] [Related]

  • 15. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity.
    Chong H, Xue J, Xiong S, Cong Z, Ding X, Zhu Y, Liu Z, Chen T, Feng Y, He L, Guo Y, Wei Q, Zhou Y, Qin C, He Y.
    J Virol; 2017 Jun 01; 91(11):. PubMed ID: 28356533
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
    Jiang X, Jia Q, Lu L, Yu F, Zheng J, Shi W, Cai L, Jiang S, Liu K.
    Amino Acids; 2016 Dec 01; 48(12):2867-2873. PubMed ID: 27631437
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors.
    Nomura W, Hashimoto C, Suzuki T, Ohashi N, Fujino M, Murakami T, Yamamoto N, Tamamura H.
    Bioorg Med Chem; 2013 Aug 01; 21(15):4452-8. PubMed ID: 23800723
    [Abstract] [Full Text] [Related]

  • 20. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
    Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.
    Viruses; 2019 Jul 03; 11(7):. PubMed ID: 31277353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.